Share on LinkedInShare on LinkedIn

ARTICLE · 06 JULY 2026

Excipient Or Active Ingredient? Look To The Marketing Authorisation…

The Advocate General has delivered a decisive opinion on whether a substance classified as an excipient in a marketing authorisation can be considered an active ingredient for Supplementary Protection Certificate eligibility purposes. This non-binding opinion addresses Halozyme's attempts to obtain SPC protection for a combination involving a substance designated as an excipient, with potentially far-reaching implications for pharmaceutical patent strategy and the relationship between regulatory classificat

United KingdomIntellectual Property

In his recently issued (non-binding) Opinion in the Halozyme referral to the Court of Justice of the EU (C-456/24), the Advocate General has delivered a decisive “no” to the question of whether a substance designated as an “excipient” in the marketing authorisation (MA) for a medicinal product can nonetheless be considered an “active ingredient” for SPC eligibility purposes. In fact, the Advocate General appears to go further, suggesting that the classification of substances in the MA is decisive for determining whether the substance can be considered an active ingredient in general.

Background

The case in question centres around Halozyme’s attempts to obtain SPC protection for the combination of trastuzumab (a monoclonal antibody) and rHuPH20 (a recombinant hyaluronidase), based on approval of the Herceptin SC product. The MA for Herceptin SC lists trastuzumab as an active ingredient, and rHuPH20 as an excipient. However, Halozyme’s position (pointing to evidence outside of the

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from